| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2016: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Myxofibrosarcoma (MFS) is a mesenchymal malignancy characterized by frequent recurrence even after radical wide resection. To optimize therapy for MFS patients, we aimed to identify candidate tissue biomarkers of MFS invasion potential. We performed protein profiling in invasive and non-invasive MFS and detected a number of differentially expressed proteins. Among them, DCBLD2 was identified as a novel factor associated with tumor cell invasion in MFS, suggesting its potential clinical application as a biomarker for MFS prognosis. This is the first report about possible clinical utility of DCBLD2 in sarcomas. Further investigation of the detected proteins may produce additional biomarkers or clinical targets in MFS.
|
